-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

Benzinga·09/22/2026 13:34:03
Diffusion vocale
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.